Key result
Post-transplant ECMO for infant graft failure is linked to an absolute ~40% lower 5-year survival.
Cohort (n=92)
Yes
Answers are grounded in this paper and cite their sources.
Retrospective multicenter study demonstrates reduced five-year survival following post-transplant ECMO in infants, indicating ECMO remains a viable rescue therapy despite higher mortality.
Primary graft failure is the major cause of mortality in infant HTx. The aim of this study was to characterize the indication and outcomes of infants requiring ECMO support due to primary graft failure after HTx. We performed a retrospective review of all infants (<1 yr) who underwent Htx from three institutions. From 1999 to 2008, 92 infants (<1 yr) received Htx. Sixteen children (17%) required ECMO after Htx due to low cardiac output syndrome. Eleven (69%) infants were successfully weaned off ECMO, and 9 (56%) infants were discharged with a mean follow-up of 2.3 ± 2.5 yr. Mean duration of ECMO in survivors was 5.4 days (2-7 days) compared with eight days (2-10 days) in non-survivors (p = NS). The five-yr survival rate for all patients was 75%; however, the five-yr survival rate was 40% in the ECMO cohort vs. 80% in the non-ECMO cohort (p = 0.0001). Graft function within one month post-Htx was similar and normal between ECMO and non-ECMO groups (shortening fraction = 42 ± 3 vs. 40 ± 2, p = NS). For infants, ECMO support for primary graft failure had a lower short-term and long-term survival rate vs. non-ECMO patients. Duration of ECMO did not adversely impact graft function and is an acceptable therapy for infants after HTx for low cardiac output syndrome.
No takes yet. Share an insight, caveat, or question.
Kaushal et al. (2013) conducted a cohort in Primary graft failure / low cardiac output syndrome after infant heart transplantation (n=92). Extracorporeal membrane oxygenation (ECMO) vs. Non-ECMO cohort was evaluated on 5-year survival rate (p=0.0001). ECMO support for primary graft failure after infant heart transplantation was associated with lower 5-year survival compared to non-ECMO patients.
Synapse has enriched 10 related papers. Consider them for comparative context: